Methyldopa should not be used with monoamine oxidase inhibitors (MAOIs), a class of medications used to treat depression. Examples of MAOIs include isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Ensam, Elderpryl, Zelapar), and rasagiline (Azilect). Combining these drugs with methyldopa may lead to dangerous side effects. At least 14 days should elapse between discontinuation of MAOIs and initiation of treatment with methyldopa.
Administration of methyldopa with iron supplements including ferrous sulfate and ferrous gluconate is not recommended as coadministration may decrease blood levels of methyldopa.
Patients taking methyldopa may require reduced doses of anesthetics during surgical procedures because of the risk of hypotension (low blood pressure). Patients undergoing surgical procedures should inform their doctor about all medications they are taking.
PREGNANCY: The safety of methyldopa in pregnant women has not been adequately evaluated.
NURSING MOTHERS: Methyldopa is known to enter breast milk. It should be used cautiously in nursing mothers.
REFERENCE: FDA Prescribing Information
Quick GuideLowering Blood Pressure Pictures Slideshow: Exercise Tips for Getting Started
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.